Dr. Boriani replied that the benefits seen with advanced pacing in this 2-year study will only become more pronounced with longer follow-up.
"Permanent atrial fibrillation is the later stage of irreversible AF, when the arrhythmia becomes untreatable. And it is a marker for adverse events, including heart failure, stroke, and death," he said.
The MINERVA trial was sponsored by Medtronic, which markets the proprietary enhanced pacing technology. Dr. Boriani reported having no relevant financial interests.